

Meeting Minutes
North Dakota Medicaid Drug Use Review (DUR) Board
Meeting Date: December 3rd, 2025
Time and Location: 1:00 pm CST in Bismarck, North Dakota

Call to Order:

A regular quarterly meeting of the North Dakota Medicaid Drug Use Review (DUR) Board meeting was convened at 1:01 pm CST with K. Martian presiding as Presiding Officer. DUR Board Coordinator, J. McKee recording minutes.

Roll Call:

Board Members Voting:

Present: Stephanie Antony, Gabriela Balf, Amanda Dahl, Andrea Honeyman, Laura Kroetsch, Kevin Martian, Paige Adkins, *Kristen Peterson*, Jessica Ziegler, *Matthew Zimny*

Absent: Amy Werremeyer, Kurt Datz

Quorum Present: Yes

Board Members Non-Voting:

Absent: Kathleen Traylor

Medicaid Pharmacy Department:

Present: Brendan Joyce, Alexi Murphy, LeNeika Roerich, Katie Steig

Absent: Jeff Hostetter

Approval of Meeting Minutes:

Motion: Moved by K. Martian to approve the minutes of the September 3, 2025 meeting, motion was seconded by A. Dahl **Motion carried.**

The minutes of the September 3, 2025, meeting were approved as distributed.

Reports:

Administrative Report: A. Murphy

Financial Report: A. Murphy

A. Murphy shared with the Board trends of reimbursement amount vs net spend for pharmacy drug claims. This information can be found in the handout.

Financial Report: Top Drugs provided by A. Murphy

A. Murphy presented the quarterly review of the top 25 drugs based on total number and cost of claims and the top 15 therapeutic classes based on number and cost of claims. This report can be found in the handout.

Retrospective Drug Utilization Review (RDUR) Report by J. McKee

J. McKee reviewed the quarterly RDUR criteria that were selected for review of each month and information from a targeted mailing. This material can be found in the handout.

Clinical Report and Annual PDL Review: Prior Authorization and Criteria Updates by J. McKee

J. McKee presented prior authorization and criteria updates with emphasis on the following sections in the PDL: Chronic Kidney Disease, Epidermolysis Bullosa, Heart Failure, Hemophilia, and Pulmonary Hypertension.

Unfinished business:

RDUR DDI Update presented to the board by J. McKee.

New business:

Second Reviews presented by J. McKee

J. McKee presented group prior authorization criteria for ANCA-Associated Vasculitis

Motion: Moved by K. Martian to place ANCA-Associated Vasculitis on prior authorization, motion was seconded by K. Peterson. **Motion carried.**

J. McKee presented group prior authorization criteria for Niemann-Pick Type C

Motion: Moved by K. Peterson to place Niemann-Pick Type C on prior authorization, motion was seconded by K. Martian. **Motion carried.**

First Reviews presented by J. McKee

J. McKee presented an overview of Non-cystic fibrosis bronchiectasis. The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Non-cystic fibrosis bronchiectasis, motion was seconded by L. Kroestch. **Motion carried.**

First Reviews presented by J. McKee

J. McKee presented an overview of PKU. The presented material can be found in the handout.

Motion: Moved by A. Dahl to draft prior authorization for PKU, motion was seconded by K. Peterson. **Motion carried.**

First Reviews presented by J. McKee

J. McKee presented an overview of Alzheimer's Disease. The presented material can be found in the handout.

Motion: Moved by K. Martian to draft prior authorization for Alzheimer's Disease, motion was seconded by S. Antony. **Motion carried.**

Retrospective Drug Utilization Review (RDUR) Criteria Recommendations:

RDUR criteria recommendations were reviewed. The presented material can be found in the handout.

Motion: Moved by K. Peterson to approve the RDUR criteria, motion was seconded by A. Dahl. **Motion carried.**

Announcements:

Next meeting is March 4, 2026.

Adjournment:

Meeting adjourned by K. Martian at 2:37 pm CST.

Date of Minutes Approval: March 4, 2026

Minutes submitted by: Julie McKee, Acentra Health